NICE recommends use of Hansa Biopharma’s Idefirix® (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients
· Idefirix® becomes the first and only product recommended by NICE for the desensitization of highly sensitized patients waiting for a kidney transplant1 · NICE considers Idefirix® to be a clinically and cost-effective treatment within current clinical practice · The positive recommendation will enable access to this novel therapy for highly sensitized patients in England, Wales and potentially Northern Ireland Lund, Sweden, June 16, 2022. Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), pioneer in enzyme technology for rare immunological conditions, today announces the